Naltrexone and Brief Counseling to Reduce Heavy Drinking: Results of a Small Clinical Trial

References

• Regier D A, Boyd J H, Burke J D, et al. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988; 45: 977–986
   PubMed Web of Science ®Google Scholar
• Hilton M. Drinking patterns and drinking problems in 1984: results from a general population survey. Alcohol Clin Exp Res 1987; 11: 167–175
   PubMed Web of Science ®Google Scholar
• Siegel P Z, Brackbill R M, Frazier E L, et al. Behavioral risk factor surveillance, 1986–1990. MMWR 1991; 40: 1–23
   PubMedGoogle Scholar
• Kranzler H R, Babor T F, Lauerman R. Problems associated with average alcohol consumption and frequency of intoxication in a medical population. Alcohol Clin Exp Res 1990; 14: 119–126
   PubMed Web of Science ®Google Scholar
• Babor T F, Ritson E B, Hodgson RJ. Alcohol-related problems in the primary health care setting: a review of early intervention strategies. Br J Addict 1986; 81: 25–46
   Google Scholar
• Babor TF. Avoiding the horrid and beastly sin of drunkenness: does dissuasion make a difference?. J Clin Consult Psychol, in press
   Google Scholar
• World Health Organization: Project on identification and management of alcohol-related problems. Report on Phase II: a randomized clinical trial of brief interventions in primary care. World Health Organization, Geneva 1992
   Google Scholar
• Froehlich J C, Harts J, Lumeng L, . En-kephalinergic involvement in voluntary ethanol consumption. Biomedical and Social Aspects of Alcohol and Alcoholism, K Kuriyama, A Takada, H. Ishii, et al. Exerpta Medica, Amsterdam, Netherlands 1988; 235–238
   Google Scholar
• Hubbell C L, Czirr S A, Hunter G A, et al. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol Clin Exp Res 1986; 3: 39–54
   Google Scholar
• Froehlich J C, Zweifel M, Harts J, et al. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology 1991; 103: 467–472
   PubMedGoogle Scholar
• Volpicelli J R, Davis M A, Olgin JE. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci 1986; 38: 841–847
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Al Alterman, Hayashida M, et al. Naltrexone and the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–880
   PubMed Web of Science ®Google Scholar
• O'Malley S, Jaffe A J, Chang G, et al. Naltrexone and alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881–887
   PubMed Web of Science ®Google Scholar
• Babor T F, de la Fuente J R, Saunders J, et al. The Alcohol Use Disorders Identification Test: Guidelines for use in primary health care. World Health Organization, Geneva 1989
   Google Scholar
• Spitzer R L, Williams J BW. Structured Clinical Interview for DSM-III-R, Patient Version. Biometric Research Department, New York State Psychiatric Institute, New York, NY 1985
   Google Scholar
• Folstein M F, Folstein S E, McHugh PR. Mini-Mental State a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–196
   PubMed Web of Science ®Google Scholar
• McLellan A T, Parikh G, Bragg A, et al. Manual for the Addiction Severity IndexFifth Edition. U.S. Government Printing Office, Washington, DC 1990
   Google Scholar
• Sobell L C, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption, R Linen, J. Allen. Humana Press, Inc., New York 1992; 41–72
   Google Scholar
• Levine J, Schooler N. Strategies for analyzing side effects data from SAFTEE. Psychopharmacol Bull 1986; 22: 343–381
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Orrok B. The pharmacotherapy of alcoholism. American Psychiatric Press Review of Psychiatry, A Tasman, RE Hales, AJ. Frances, Washington, DC 1989; Vol 8: 359–379
   Google Scholar
• Bohn MJ. Pharmacotherapy of alcoholism. Psychiatr Clin North Am 1993; 16: 679–692
   Google Scholar
• Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 1984; 3: 273–280
   PubMedGoogle Scholar
• Tempel A, Zukin R S, Gardner EL. Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci 1982; 31: 1401–1404
   PubMed Web of Science ®Google Scholar
• Krahn D D, Kurth C, Demitrack M A, et al. The relationship of dieting to alcohol and other drug use in young women. J Subst Abuse 1993; 4: 341–354
   Google Scholar
• Yung L, Gordis E, Holt J. Dietary choices and likelihood of abstinence among alcoholic patients in an outpatient clinic. Drug Alcohol Depend 1983; 12: 355–362
   Google Scholar
• Marks-Kaufman R, Kanarek RB. Diet selection following a chronic morphine and naloxone regimen. Pharmacol Biochem Behav 1990; 35: 665–669
   PubMed Web of Science ®Google Scholar
• Gosnell B A, Krahn DD. The effects of continuous naltrexone infusions on diet preferences are modulated by adaptation to the diets. Physiol Behav 1992; 51: 239–244
   PubMed Web of Science ®Google Scholar
• Drenowski A, Krahn D D, Demitrack M A, et al. Opioid effects on taste preferences and food consumption: a comparison of female binge eaters and controls. Physiol Behav 1992; 51: 371–379
   Google Scholar